Ionization Feasibility
Avoid unproductive screening by establishing whether the API offers a credible and useful salt-forming opportunity.
- Ionizable-site and microstate review
- pKa and ΔpKa assessment
- Charge and stoichiometry hypotheses
AI for Pharmaceutical Solid Form Development
AI for Salt Form Selection
Select a pharmaceutical salt for the product it must become—not simply because a crystalline material can be isolated. CD ComputaBio combines ionization analysis, counterion intelligence, solid-state screening, and developability assessment to nominate salt forms that can survive formulation, processing, and storage.
Chemistry qualifiedpKa, charge state, counterion fit
Product focusedSolubility, stability, processing
Control mindedConversion and disproportionation risk
Service coverage
Salt Form Selection Services
Counterion Prioritization
Focus material on counterions compatible with the API, intended route, safety context, and desired property change.
- Acid/base pairing rationale
- Route and precedent filters
- Solvent–counterion planning
Salt Candidate Screening
Expand the experimental space beyond a single preparation condition while preserving material efficiency.
- Stoichiometry and solvent variation
- Slurry, cooling, evaporation, antisolvent
- Phase identity and reproducibility checks
Developability Profiling
Reveal candidates that improve one property but introduce moisture, stability, isolation, or conversion liabilities.
- Solubility and dissolution behavior
- Thermal and humidity response
- Disproportionation challenge
Salt Selection & Control
Nominate a primary form and backup using transparent trade-offs tied to formulation and manufacturing decisions.
- Target-product-profile ranking
- Primary and backup rationale
- Follow-on form-control plan
Salt decision profile
Salt Candidate Evaluation
A large solubility increase does not compensate for poor isolation, excessive hygroscopicity, excipient-driven disproportionation, or multiple competing phases. We compare benefit, robustness, and evidence confidence rather than selecting on a single measurement.
Ionization fit
Solubility benefit
Solid robustness
Processability
Control confidence
Lower suitabilityIllustrative comparisonHigher suitability
Adaptive strategy
Salt Selection Workflow
01
Define the product constraint
Connect the free-form liability to route, dose, formulation, exposure, process, storage, and critical quality requirements.
02
Qualify salt-forming chemistry
Resolve likely charge states, pKa relationships, reactive functions, stoichiometry options, and counterion exclusions.
03
Generate diverse salt phases
Combine prioritized counterions with solvent, temperature, ratio, slurry, cooling, evaporation, and antisolvent conditions.
04
Stress the attractive candidates
Test humidity, thermal exposure, pH, excipient contact, aqueous media, and slurry conditions for conversion or disproportionation.
05
Nominate and define controls
Rank performance and manufacturability, select primary and backup salts, and specify the next polymorph, process, and stability studies.
Project readiness
Project Inputs and Deliverables
Recommended inputs
- API structure, stereochemistry, ionizable groups, pKa data or estimates
- Free-form solubility, crystallinity, stability, and moisture behavior
- Route, dose, formulation concept, and exposure requirements
- Existing counterion trials, analytical data, and material constraints
Decision controls
- Traceable counterion inclusion and exclusion rationale
- Orthogonal confirmation of salt identity and phase purity
- Early disproportionation and hydrate/solvate challenges
- Explicit trade-offs, uncertainties, and backup-form logic
01Counterion strategy
02Salt candidate set
03Developability matrix
04Selection & control dossier
Published data
CASE 01 · COUNTERION ACIDITY
CASE 02 · DISPROPORTIONATION
Published Salt Selection Studies
The schematics below are original method-to-decision summaries created for this page; they do not reproduce publication figures or represent CD ComputaBio project results.
A replacement salt was selected after the first choice failed development
Development failureRecognize inadequate stability during scale-up synthesis and storage.
→
Alternative saltsCompare counterion acidity and pH–solubility behavior for new candidates.
→
Selection decisionBalance stability, solubility, and biopharmaceutical intent before nomination.
Counterion acidityScale-up stabilitypH–solubilityProduct performance
Tong and colleagues described a salt-selection roadmap in which an initially selected salt became undevelopable, demonstrating why successful crystallization must be followed by comparative developability assessment.[1]
View publicationMicroenvironmental pH can reverse the advantage of a salt
Risk driversConsider pHmax, API/counterion pKa, moisture, buffering, and excipients.
→
Stress challengeEvaluate conversion to the free form during formulation and storage.
→
Control actionRank risk and define analytical monitoring or formulation mitigation.
pHmaxExcipient effectsMoisture stressFree-form conversion
Thakral and Kelly reviewed salt disproportionation from a materials-science perspective, linking microenvironmental pH and excipient effects to physical stability and dissolution risk.[2]
View publicationProject decision guide
Salt Form Selection FAQs
Salt choice depends on API chemistry, dosage form, route, dose, and product risk; no counterion is universally optimal.
Is ΔpKa enough to predict successful salt formation?
No. ΔpKa is a useful feasibility indicator, but ionization in the solid, crystallization, stoichiometry, solvation, kinetics, and competing phases still require experimental confirmation.
Should the most soluble salt always be selected?
No. High apparent solubility can coexist with hygroscopicity, chemical instability, poor isolation, disproportionation, or precipitation of the free form.
How are counterions chosen?
Counterions are prioritized by pKa fit, route-appropriate safety, chemical compatibility, regulatory precedent, desired property change, crystallization behavior, and project constraints.
Can an existing salt screen be rescued?
Yes. Existing results can be audited for counterion coverage, analytical assignments, missing stress conditions, and unclear decision criteria before targeted follow-up work is designed.
What happens after a salt is nominated?
The selected salt typically requires dedicated polymorph, hydrate/solvate, crystallization-process, compatibility, and stability studies to establish a reproducible control strategy.
Plan your salt-selection program
Request a Project PlanStart Your Salt Form Project
Share your API structure, free-form liabilities, dosage-form target, and existing screen data. CD ComputaBio will propose a decision-focused counterion and salt-candidate strategy.
Scientific References
- Tong, W.-Q. T., Whitesell, G., D'Souza, C., et al. The Selection of a Pharmaceutical Salt—The Effect of the Acidity of the Counterion on Its Solubility and Potential Biopharmaceutical Performance. Journal of Pharmaceutical Sciences 107(1), 419–425 (2018). https://doi.org/10.1016/j.xphs.2017.10.032
- Thakral, N. K. & Kelly, R. C. Salt disproportionation: A material science perspective. International Journal of Pharmaceutics 520(1–2), 228–240 (2017). https://doi.org/10.1016/j.ijpharm.2017.02.001
